doxapram has been researched along with Obstructive Lung Diseases in 20 studies
Doxapram: A central respiratory stimulant with a brief duration of action. (From Martindale, The Extra Pharmocopoeia, 30th ed, p1225)
doxapram : A member of the class of pyrrolidin-2-ones that is N-ethylpyrrolidin-2-one in which both of the hydrogens at the 3 position (adjacent to the carbonyl group) are substituted by phenyl groups, and one of the hydrogens at the 4 position is substituted by a 2-(morpholin-4-yl)ethyl group. A central and respiratory stimulant with a brief duration of action, it is used (generally as the hydrochloride or the hydrochloride hydrate) as a temporary treatment of acute respiratory failure, particularly when superimposed on chronic obstructive pulmonary disease, and of postoperative respiratory depression. It has also been used for treatment of postoperative shivering.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We report three cases in which doxapram hydrochloride injection was used as an additional method of treating and stabilizing patients with chronic hypercapnia and hypoxia." | 7.69 | Use of doxapram hydrochloride injection as an alternative to intubation to treat chronic obstructive pulmonary disease patients with hypercapnia. ( Dupper, RL; Hirshberg, AJ, 1994) |
| "We report three cases in which doxapram hydrochloride injection was used as an additional method of treating and stabilizing patients with chronic hypercapnia and hypoxia." | 3.69 | Use of doxapram hydrochloride injection as an alternative to intubation to treat chronic obstructive pulmonary disease patients with hypercapnia. ( Dupper, RL; Hirshberg, AJ, 1994) |
| "Doxapram is a respiratory stimulant used to stimulate respiration in this setting." | 2.42 | Doxapram for ventilatory failure due to exacerbations of chronic obstructive pulmonary disease. ( Greenstone, M; Lasserson, TJ, 2003) |
| "Doxapram is a respiratory stimulant used to stimulate breathing in this setting." | 2.41 | Doxapram for ventilatory failure due to exacerbations of chronic obstructive pulmonary disease. ( Greenstone, M, 2000) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 10 (50.00) | 18.7374 |
| 1990's | 8 (40.00) | 18.2507 |
| 2000's | 2 (10.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Greenstone, M | 2 |
| Lasserson, TJ | 1 |
| Hirshberg, AJ | 1 |
| Dupper, RL | 1 |
| Bott, J | 1 |
| Carroll, MP | 1 |
| Conway, JH | 1 |
| Keilty, SE | 1 |
| Ward, EM | 1 |
| Brown, AM | 1 |
| Paul, EA | 1 |
| Elliott, MW | 1 |
| Godfrey, RC | 1 |
| Wedzicha, JA | 1 |
| Moxham, J | 1 |
| Angus, RM | 1 |
| Ahmed, AA | 1 |
| Fenwick, LJ | 1 |
| Peacock, AJ | 1 |
| Kiszka-Kanowitz, M | 1 |
| Matzen, P | 1 |
| Cooper, C | 1 |
| Whittle, A | 1 |
| Conti, F | 2 |
| Bertoli, L | 2 |
| Bertoli, M | 1 |
| Mantero, O | 2 |
| Jeffrey, AA | 1 |
| Warren, PM | 1 |
| Flenley, DC | 1 |
| Pourriat, JL | 2 |
| Baud, M | 2 |
| Lamberto, C | 2 |
| Fosse, JP | 1 |
| Cupa, M | 2 |
| Hoang, P | 1 |
| Aitkaci, F | 1 |
| Vasseur, B | 1 |
| Akiyama, Y | 1 |
| Kawakami, Y | 2 |
| Yoshikawa, T | 1 |
| Yamamoto, H | 1 |
| Nishimura, M | 1 |
| Sochocky, S | 1 |
| Shepperd, JD | 1 |
| Moser, KM | 1 |
| Luchsinger, PC | 1 |
| Adamson, JS | 1 |
| McMahon, SM | 1 |
| Schlueter, DP | 1 |
| Spivack, M | 1 |
| Weg, JG | 1 |
| Norman, JR | 1 |
| Proctor, CA | 1 |
| Conerly, AW | 1 |
| Fritts, HW | 1 |
| Rochester, DF | 1 |
5 reviews available for doxapram and Obstructive Lung Diseases
| Article | Year |
|---|---|
Doxapram for ventilatory failure due to exacerbations of chronic obstructive pulmonary disease.
Topics: Acute Disease; Doxapram; Humans; Lung Diseases, Obstructive; Randomized Controlled Trials as Topic; | 2003 |
Doxapram for ventilatory failure due to exacerbations of chronic obstructive pulmonary disease.
Topics: Acute Disease; Doxapram; Humans; Lung Diseases, Obstructive; Respiratory Insufficiency; Respiratory | 2000 |
[Treatment of acute hypercapnic respiratory insufficiency in chronic obstructive bronchopneumopathy. New trends in controlled oxygen therapy].
Topics: Adult; Aged; Aminophylline; Chronic Disease; Doxapram; Female; Humans; Hypercapnia; Lung Diseases, O | 1975 |
[Are respiratory stimulants necessary? No].
Topics: Almitrine; Central Nervous System Stimulants; Chemoreceptor Cells; Doxapram; Humans; Lung Diseases, | 1987 |
Cor pulmonale.
Topics: Adrenal Cortex Hormones; Anti-Bacterial Agents; Bronchodilator Agents; Central Nervous System Stimul | 1974 |
4 trials available for doxapram and Obstructive Lung Diseases
| Article | Year |
|---|---|
Randomised controlled trial of nasal ventilation in acute ventilatory failure due to chronic obstructive airways disease.
Topics: Adrenal Cortex Hormones; Anti-Bacterial Agents; Blood; Bronchodilator Agents; Carbon Dioxide; Doxapr | 1993 |
Comparison of the acute effects on gas exchange of nasal ventilation and doxapram in exacerbations of chronic obstructive pulmonary disease.
Topics: Doxapram; Female; Humans; Intermittent Positive-Pressure Ventilation; Lung Diseases, Obstructive; Ma | 1996 |
Ventilatory and pulmonary hemodynamic response to the respiratory stimulant doxapram in chronic bronchitis.
Topics: Aged; Blood Pressure; Bronchitis; Chronic Disease; Clinical Trials as Topic; Doxapram; Female; Heart | 1976 |
Respiratory stimulation with intravenous doxapram in respiratory failure. A double-blind co-operative study.
Topics: Adult; Aged; Carbon Dioxide; Clinical Trials as Topic; Doxapram; Female; Follow-Up Studies; Humans; | 1973 |
11 other studies available for doxapram and Obstructive Lung Diseases
| Article | Year |
|---|---|
Use of doxapram hydrochloride injection as an alternative to intubation to treat chronic obstructive pulmonary disease patients with hypercapnia.
Topics: Aged; Blood Gas Analysis; Doxapram; Female; Humans; Hypercapnia; Infusions, Intravenous; Lung Diseas | 1994 |
[Doxapram treatment in acute deterioration of chronic obstructive pulmonary disease].
Topics: Doxapram; Humans; Lung Diseases, Obstructive; Respiratory System Agents | 1997 |
Respiratory disease. Congestion at British airways.
Topics: Disease Management; Doxapram; Humans; Lung Diseases, Obstructive; Patient Education as Topic; Practi | 1998 |
COPD guidelines.
Topics: Doxapram; Humans; Lung Diseases, Obstructive; Practice Guidelines as Topic; Respiration, Artificial; | 1999 |
Acute hypercapnic respiratory failure in patients with chronic obstructive lung disease: risk factors and use of guidelines for management.
Topics: Doxapram; Female; Humans; Hydrogen-Ion Concentration; Hypercapnia; Lung Diseases, Obstructive; Male; | 1992 |
Effects of doxapram on hypercapnic response during weaning from mechanical ventilation in COPD patients.
Topics: Aged; Carbon Dioxide; Doxapram; Female; Humans; Hypercapnia; Infusions, Intravenous; Lung Diseases, | 1992 |
[Effects of doxapram on the response to hypercapnia: application to weaning from artificial ventilation in chronic obstructive respiratory insufficiency].
Topics: Aged; Doxapram; Humans; Hypercapnia; Lung Diseases, Obstructive; Middle Aged; Ventilator Weaning | 1989 |
Doxapram on blunted respiratory chemosensitivity to hypoxia in hypoxemic, chronic obstructive pulmonary disease.
Topics: Adolescent; Adult; Aged; Bronchitis; Chemoreceptor Cells; Doxapram; Female; Forced Expiratory Flow R | 1987 |
Experience with the use of doxapram in the treatment of respiratory failure.
Topics: Central Nervous System Stimulants; Doxapram; Humans; Lung Diseases, Obstructive; Morpholines; Oxygen | 1972 |
Respiratory failure in chronic airways obstruction.
Topics: Aerosols; Anti-Bacterial Agents; Blood Gas Analysis; Chronic Disease; Doxapram; Drainage; Exercise T | 1973 |
Respiratory stimulants and obstructed airways.
Topics: Airway Obstruction; Doxapram; Humans; Lung Diseases, Obstructive; Oxygen Inhalation Therapy; Respira | 1973 |